Loading stock data…
DCTH
$11.69+0.75 (+6.86%)
Market ClosedLast close Jun 9
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Delcath Systems, Inc. in the Healthcare sector is trading at $11.69. Wall Street consensus targets $21.29 (6 analysts), implying a +82.1% move over the next 12 months. The stock is currently 29% below its 52-week high of $16.56, remaining 14.4% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +82.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$11.69
Potential Downside
0%
Whystock Fair Value$11.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delive...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.50%
Volume
Today's trading volume
1.04M
Recent News
Delcath (DCTH) Q1 2026 Earnings Transcript
David Hoffman: Thank you, and welcome to Delcath Systems First Quarter 2026 Earnings Call. With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, Chief Financial Officer; Kevin Muir, Chief Commercial Officer; Vojislav Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer.
Delcath Systems Q1 Earnings Call Highlights
Delcath Systems (NASDAQ:DCTH) reported first-quarter 2026 revenue growth and reiterated its full-year outlook, while updating expectations for U.S. treatment-center activations and outlining progress across ongoing clinical programs. Executives pointed to record new patient starts and the impact of
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems (DCTH) delivered earnings and revenue surprises of -200.00% and -0.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 Guidance
Analysts now reference a revised US$27 price target for Delcath Systems, while the model based Fair Value remains steady at US$21.33. Bullish voices see that US$27 level as still offering upside relative to current trading, backed by FY26 sales guidance of at least US$100m and increased spending on HEPZATO related R&D and commercial expansion, while more cautious views focus on the gap to the US$111m consensus and higher operating costs. Read on to see how to track these competing narratives...
Implied Volatility Surging for Delcath Systems Stock Options
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.